
    
      Currently, the only management options for AAA are surgical (open or endovascular) based on
      ongoing follow-up with imaging at regular intervals. Telmisartan is currently approved for
      use in the United States by the Food and Drug Administration for management of hypertension.
      If telmisartan is found to be effective in slowing the progression of abdominal aortic
      aneurysms, this would provide a new treatment option for patients with AAA disease.
    
  